pharmaceutical investing Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial
pharmaceutical investing Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer
Homerun Resources Inc. Files for Approval of $3 Million Financing; Updates $6 Million Institutional Financing
